TECENTRIQ (Roche Products Pty Ltd)
Product name
TECENTRIQ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
194 working days (255)
Active ingredients
atezolizumab
Registration type
EOI
Indication
TECENTRIQ (concentrated solution for injection), in combination with nab-paclitaxel and carboplatin, is now also indicated for first-line treatment of patients with metastatic non-squamous NSCLC who do not have tumour EGFR or ALK genomic aberrations.